Patents by Inventor Robert William Gristwood

Robert William Gristwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF BETHANECHOL FOR TREATMENT OF XEROSTOMIA
    Publication number: 20160287512
    Abstract: Bethanechol is administered topically, for the treatment of xerostomia.
    Type: Application
    Filed: April 6, 2016
    Publication date: October 6, 2016
    Inventors: Nicola Cooper, Julian Clive Gilbert, Robert William Gristwood, Michael Grant Wyllie
  • USE OF BETHANECHOL FOR TREATMENT OF XEROSTOMIA
    Publication number: 20150366794
    Abstract: Bethanecol is administered topically, for the treatment of xerostomia.
    Type: Application
    Filed: September 1, 2015
    Publication date: December 24, 2015
    Inventors: Nicola Cooper, Julian Clive Gilbert, Robert William Gristwood, Michael Grant Wyllie
  • Use of Amisulpride as an Anti-Emetic
    Publication number: 20150335616
    Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
    Type: Application
    Filed: July 29, 2015
    Publication date: November 26, 2015
    Inventors: Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox
  • Use of bethanechol for treatment of xerostomia
    Patent number: 9149454
    Abstract: Bethanechol is administered topically, for the treatment of xerostomia.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: October 6, 2015
    Assignee: Acacia Pharma Limited
    Inventors: Nicola Cooper, Julian Clive Gilbert, Robert William Gristwood, Michael Grant Wyllie
  • Use of amisulpride as an anti-emetic
    Patent number: 9119836
    Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: September 1, 2015
    Assignee: Acacia Pharma Limited
    Inventors: Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox
  • Use of amisulpride as an anti-emetic
    Patent number: 9084765
    Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: July 21, 2015
    Assignee: Acacia Pharma Limited
    Inventors: Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox
  • Use of Amisulpride as an Anti-Emetic
    Publication number: 20140147517
    Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
    Type: Application
    Filed: February 4, 2014
    Publication date: May 29, 2014
    Inventors: Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox
  • Use of amisulpride as an anti-emetic
    Patent number: 8686019
    Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: April 1, 2014
    Assignee: Acacia Pharma Limited
    Inventors: Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox
  • Drug combination and its use in the treatment of muscle loss
    Patent number: 8653052
    Abstract: The present invention is a product comprising a ?2 agonist and a progestin, as a combined preparation for separate, simultaneous or sequential use in the treatment or prevention of muscle loss. The present invention is also a ?2 agonist selected from R,R-formoterol, indacaterol or ritodrine, for use in the treatment or prevention of muscle loss.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: February 18, 2014
    Assignee: Acacia Pharma Limited
    Inventors: Julian Clive Gilbert, Robert William Gristwood
  • Use of Amisulpride as an Anti-Emetic
    Publication number: 20130022689
    Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
    Type: Application
    Filed: July 26, 2012
    Publication date: January 24, 2013
    Inventors: Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox
  • Use of Bethaneciol for Treatment of Xerostomia
    Publication number: 20120232137
    Abstract: Bethanechol is administered topically, for the treatment of xerostomia.
    Type: Application
    Filed: November 11, 2010
    Publication date: September 13, 2012
    Inventors: Nicola Cooper, Julian Clive Gilbert, Robert William Gristwood, Michael Grant Wyllie
  • Drug Combination and Its Use in the Treatment of Muscle Loss
    Publication number: 20100130456
    Abstract: The present invention is a product comprising a ?2 agonist and a progestin, as a combined preparation for separate, simultaneous or sequential use in the treatment or prevention of muscle loss. The present invention is also a ?2 agonist selected from R,R-formoterol, indacaterol or ritodrine, for use in the treatment or prevention of muscle loss.
    Type: Application
    Filed: April 24, 2008
    Publication date: May 27, 2010
    Inventors: Julian Clive Gilbert, Robert William Gristwood
  • NEW THERAPEUTIC USE OF 4-(2-FLUOROPHENYL)-6-METHYL-2-(1-PIPERAZINYL)THIENO[2,3-D]PYRIMIDINE
    Publication number: 20090215791
    Abstract: 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof is useful for the treatment of pain.
    Type: Application
    Filed: August 28, 2008
    Publication date: August 27, 2009
    Applicant: Dynogen Pharmaceuticals, Inc.
    Inventors: Hazel Judith Bardsley, David Cavalla, Robert William Gristwood
  • 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder
    Patent number: 7470690
    Abstract: Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof for the manufacture of a medicament for the treatment of functional bowel disorder.
    Type: Grant
    Filed: July 9, 2003
    Date of Patent: December 30, 2008
    Assignee: Dynogen Pharmaceuticals, Inc.
    Inventors: David Cavalla, Robert William Gristwood
  • Use of 4-(2-Flurophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-D)-pyrimidine for treating of urinary incontinence
    Patent number: 7220748
    Abstract: 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)-Thieno(2,3-D)pyrimidine or a salt thereof is useful for the treatment of urinary incontinence.
    Type: Grant
    Filed: January 29, 2003
    Date of Patent: May 22, 2007
    Assignee: Arachnova Therapeutics Ltd.
    Inventors: David Cavalla, Robert William Gristwood
  • Arylazo-substituted imidazole for the treatment of stress urinary incontinence
    Publication number: 20040242547
    Abstract: An arylazo-substituted imidazole having adrenergic alpha stimulatory activity, is useful for the treatment of stress urinary incontinence.
    Type: Application
    Filed: July 22, 2004
    Publication date: December 2, 2004
    Inventors: Robert William Gristwood, David Cavalla
  • New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
    Publication number: 20040048874
    Abstract: 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof is useful for the treatment of pain.
    Type: Application
    Filed: July 10, 2003
    Publication date: March 11, 2004
    Inventors: Hazel Judith Bardsley, David Cavalla, Robert William Gristwood
  • Levobupivacaine as an analgesic agent
    Patent number: 6417201
    Abstract: Levobupivacaine ((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide) is useful as an anesthetic, particularly in a patient who is disposed to adverse systemic side-effects, e.g., one who is CNS-compromised or predisposed to CNS side-effects. A unit dose of levobupivacaine comprising at least 75 mg to less than 200 mg of levobupivacaine is described herein.
    Type: Grant
    Filed: July 12, 2000
    Date of Patent: July 9, 2002
    Assignee: Darwin Discovery, Ltd.
    Inventors: Hazel Judith Bardsley, Robert William Gristwood, Andrew John McGlashan Richards
  • Analgesic agent and its use
    Patent number: 6103741
    Abstract: Aqueous pharmaceutical compositions comprising levobupivacaine((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide ), that are particularly useful in a patient who is disposed to adverse systemic side-effects, are disclosed.
    Type: Grant
    Filed: December 14, 1998
    Date of Patent: August 15, 2000
    Assignee: Darwin Discovery, Ltd.
    Inventors: Hazel Judith Bardsley, Robert William Gristwood, Andrew John McGlashan Richards
  • Use of levobupivacaine as an anesthetic agent
    Patent number: 5849763
    Abstract: Levobupivacaine ((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide) is useful as an anesthetic, particularly in a patient who is CNS-compromised or predisposed to CNS side-effects. It is also useful as an anesthetic in obstetrics.
    Type: Grant
    Filed: October 27, 1995
    Date of Patent: December 15, 1998
    Assignee: Darwin Discovery Limited
    Inventors: Hazel Judith Bardsley, Robert William Gristwood, Andrew John McGlashan Richards